New Alzheimer’s Drugs Raise Questions for Regulators
Key Points Summary New Alzheimer’s drugs such as donanemab and lecanemab are generating optimism but remain controversial due to modest
Read MoreKey Points Summary New Alzheimer’s drugs such as donanemab and lecanemab are generating optimism but remain controversial due to modest
Read More